Ken Griffin Adicet Bio, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$1.07 - $1.63 $107 - $163	-100 Reduced 2.33%	4,200 $6,000
Q2 2024 Aug 14, 2024	SELL	$1.21 - $2.4 $10,890 - $21,600	-9,000 Reduced 67.67%	4,300 $5,000
Q1 2024 May 15, 2024	BUY	$1.76 - $3.45 $20,416 - $40,020	11,600 Added 682.35%	13,300 $31,000
Q4 2023 Feb 14, 2024	SELL	$1.11 - $1.89 $999 - $1,701	-900 Reduced 34.62%	1,700 $3,000
Q3 2023 Nov 14, 2023	SELL	$1.37 - $3.4 $10,138 - $25,160	-7,400 Reduced 74.0%	2,600 $3,000
Q2 2023 Aug 14, 2023	SELL	$2.13 - $7.13 $27,690 - $92,690	-13,000 Reduced 56.52%	10,000 $24,000
Q1 2023 May 15, 2023	SELL	$5.52 - $9.23 $11,592 - $19,383	-2,100 Reduced 8.37%	23,000 $132,000
Q4 2022 Feb 14, 2023	BUY	$7.72 - $21.27 $113,484 - $312,669	14,700 Added 141.35%	25,100 $224,000
Q3 2022 Nov 14, 2022	SELL	$13.43 - $18.74 $208,165 - $290,470	-15,500 Reduced 59.85%	10,400 $148,000

59.2M

4.2K

6.7K

Ticker ACET
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,030,800
Market Cap $44M
Description
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.